CLINICAL RESEARCH: MYOCARDIAL INFARCTION
Effects of Intravenous Atrial Natriuretic Peptide on Cardiac Sympathetic Nerve Activity and Left Ventricular Remodeling in Patients With First Anterior Acute Myocardial Infarction
Shu Kasama, MD*,*,
Takuji Toyama, MD*,
Takashi Hatori, MD*,
Hiroyuki Sumino, MD*,
Hisao Kumakura, MD ,
Yoshiaki Takayama, MD,
Shuichi Ichikawa, MD,
Tadashi Suzuki, MD* and
Masahiko Kurabayashi, MD*
* Department of Cardiovascular Medicine, Gunma University School of Medicine, Maebashi, Japan
Department of Internal Medicine, Cardiovascular Hospital of Central Japan, Gunma, Japan.
Manuscript received April 24, 2006;
revised manuscript received August 22, 2006,
accepted September 18, 2006.
* Reprint requests and correspondence: Dr. Shu Kasama, Department of Cardiovascular Medicine, Gunma University School of Medicine, 3-39-15, Showa-machi, Maebashi, Gunma 371-0034, Japan. (Email: s-kasama{at}bay.wind.ne.jp).
Objectives: We sought to evaluate the effects of atrial natriuretic peptide (ANP) on cardiac sympathetic nerve activity (CSNA) and left ventricular (LV) remodeling in patients with first anterior acute myocardial infarction (AMI) after primary coronary angioplasty.
Background: The activation of the renin-angiotensin-aldosterone system (RAAS) prevents the uptake of norepinephrine in the myocardium. Atrial natriuretic peptide, a circulating hormone of cardiac origin, has vasodilatory and diuretic properties, and can inhibit the RAAS.
Methods: We studied 50 patients with first anterior AMI who were randomly assigned to receive ANP (group A) or isosorbide dinitrate (group B) before and after primary coronary angioplasty. The ANP or ISDN was continuously infused >48 h. The extent score (ES) was determined from 99mTc-pyrophosphate scintigraphy to evaluate the area of initial myocardial damage 3 to 5 days after primary angioplasty. The LV end-diastolic volume (LVEDV) and LV ejection fraction (LVEF) were determined by left ventriculography 2 weeks later. The delayed heart/mediastinum count (H/M) ratio, delayed total defect score (TDS), and washout rate (WR) were determined from 123I-meta-iodobenzylguanidine scintigraphy after 3 weeks.
Results: After primary angioplasty, age, gender, risk factors, peak serum creatine phosphokinase concentration, recanalization time, and ES were similar in the 2 groups. However, in group A (n = 25), the TDS was significantly lower (34 ± 8 vs. 41 ± 8; p < 0.05), the H/M ratio was significantly higher (1.96 ± 0.18 vs. 1.74 ± 0.23; p < 0.05), and the WR was significantly lower (35 ± 8% vs. 44 ± 12%; p < 0.005) than in group B (n = 25). Moreover, the LVEDV and LVEF in group A were better than in group B (LVEDV: 85.5 ± 28.5 ml vs. 106.3 ± 39.4 ml [p < 0.05]; LVEF: 47.9 ± 10.2% vs. 41.5 ± 11.8% [p < 0.05]).
Conclusions: Intravenous ANP improves CSNA and prevents LV remodeling in patients with first anterior AMI.
|
Abbreviations and Acronyms
| | 123I-MIBG = 123I-meta-iodobenzylguanidine | | 99mTc-PYP = 99mTc-pyrophosphate | | AMI = acute myocardial infarction | | ANP = atrial natriuretic peptide | | ES = extent score | | H/M = heart/mediastinum count | | ISDN = isosorbide dinitrate | | LV = left ventricular | | LVEDP = left ventricular end-diastolic pressure | | LVEDV = left ventricular end-diastolic volume | | LVEF = left ventricular ejection fraction | | TDS = total defect score | | WR = washout rate |
|
This article has been cited by other articles:
|
|
|
|
 
S. Kasama, T. Toyama, H. Sumino, H. Kumakura, Y. Takayama, K. Minami, S. Ichikawa, N. Matsumoto, Y. Sato, and M. Kurabayashi
Effects of spironolactone on cardiac sympathetic nerve activity and left ventricular remodelling after reperfusion therapy in patients with first ST-segment elevation myocardial infarction
Heart,
May 15, 2011;
97(10):
817 - 822.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kasama, T. Toyama, H. Sumino, H. Kumakura, Y. Takayama, K. Minami, S. Ichikawa, N. Matsumoto, Y. Sato, and M. Kurabayashi
Prognostic value of cardiac sympathetic nerve activity evaluated by [123I]m-iodobenzylguanidine imaging in patients with ST-segment elevation myocardial infarction
Heart,
January 1, 2011;
97(1):
20 - 26.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Sezai, M. Hata, T. Niino, I. Yoshitake, S. Unosawa, S. Wakui, K. Fujita, T. Takayama, Y. Kasamaki, A. Hirayama, et al.
Continuous Low-Dose Infusion of Human Atrial Natriuretic Peptide in Patients With Left Ventricular Dysfunction Undergoing Coronary Artery Bypass Grafting: The NU-HIT (Nihon University working group study of low-dose Human ANP Infusion Therapy during cardiac surgery) for Left Ventricular Dysfunction
J. Am. Coll. Cardiol.,
April 27, 2010;
55(17):
1844 - 1851.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Sezai, M. Hata, T. Niino, I. Yoshitake, S. Unosawa, S. Wakui, S. Osaka, T. Takayama, Y. Kasamaki, A. Hirayama, et al.
Influence of Continuous Infusion of Low-Dose Human Atrial Natriuretic Peptide on Renal Function During Cardiac Surgery: A Randomized Controlled Study
J. Am. Coll. Cardiol.,
September 15, 2009;
54(12):
1058 - 1064.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H H Chen, F L Martin, R J Gibbons, J A Schirger, R S Wright, R M Schears, M M Redfield, R D Simari, A Lerman, A Cataliotti, et al.
Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study
Heart,
August 15, 2009;
95(16):
1315 - 1319.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A M. Richards
Therapeutic potential of infused cardiac natriuretic peptides in myocardial infarction
Heart,
August 15, 2009;
95(16):
1299 - 1300.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. George, B. Morrow, K. Xu, G.-H. Yi, J. Holmes, E. X. Wu, Z. Li, A. A. Protter, M. C. Oz, and J. Wang
Prolonged effects of B-type natriuretic peptide infusion on cardiac remodeling after sustained myocardial injury
Am J Physiol Heart Circ Physiol,
August 1, 2009;
297(2):
H708 - H717.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ishii, T. Amano, T. Matsubara, and T. Murohara
Pharmacological Intervention for Prevention of Left Ventricular Remodeling and Improving Prognosis in Myocardial Infarction
Circulation,
December 16, 2008;
118(25):
2710 - 2718.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kasama, M. Furuya, T. Toyama, S. Ichikawa, and M. Kurabayashi
Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction
Eur. Heart J.,
June 2, 2008;
29(12):
1485 - 1494.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kasama, T. Toyama, H. Sumino, M. Nakazawa, N. Matsumoto, Y. Sato, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, et al.
Prognostic Value of Serial Cardiac 123I-MIBG Imaging in Patients with Stabilized Chronic Heart Failure and Reduced Left Ventricular Ejection Fraction
J. Nucl. Med.,
June 1, 2008;
49(6):
907 - 914.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. W Yip
B-type natriuretic peptide: a treatment, not a diagnostic marker
Heart,
May 1, 2008;
94(5):
542 - 544.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al.
Highlights of the Year in JACC 2007
J. Am. Coll. Cardiol.,
January 29, 2008;
51(4):
490 - 512.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kasama, T. Toyama, H. Sumino, N. Matsumoto, Y. Sato, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, and M. Kurabayashi
Additive Effects of Spironolactone and Candesartan on Cardiac Sympathetic Nerve Activity and Left Ventricular Remodeling in Patients with Congestive Heart Failure
J. Nucl. Med.,
December 1, 2007;
48(12):
1993 - 2000.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kasama, T. Toyama, H. Sumino, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, and M. Kurabayashi
Long-Term Nicorandil Therapy Improves Cardiac Sympathetic Nerve Activity After Reperfusion Therapy in Patients with First Acute Myocardial Infarction
J. Nucl. Med.,
October 1, 2007;
48(10):
1676 - 1682.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
